Navamedic

Regulatory Filings • Dec 9, 2025

Oslo, December 9, 2025 - Navamedic ASA Introduces Flexilev[®] in OraFID[®]: Enhancing Parkinson's Care with Simplified and Precise Dosing for Personalized Treatment

Oslo, December 9, 2025 - Navamedic ASA Introduces Flexilev[®] in OraFID[®]: Enhancing Parkinson's Care with Simplified and Precise Dosing for Personalized Treatment

Navamedic ASA is excited to announce the launch of Flexilev[®] in OraFID[®], a

novel, single-use dosing dispenser specifically designed to deliver precise and

personalized Parkinson's treatment in a user-friendly format. The product will

be available for prescription at pharmacies late December/early January.

As Parkinson's disease advances, patients frequently experience variations in

motor abilities throughout the day. For those facing reduced efficacy towards

the end of the dosing interval (dose gaps) the OraFID[®] dispenser provides an

enhanced opportunity to fine tune levodopa treatment.

This combination of drug and device allows for dosing adjustments to address

each patient's specific requirements at any given time, thereby minimizing the

risk of under- or overdosing and associated side effects. It offers a simplified

approach to achieving precise medication delivery.

Kathrine Gamborg Andreassen, CEO of Navamedic ASA, states: "This concept

reflects our unwavering commitment to be a proud contributor to public health by

improving patient outcomes through personalized treatment solutions, utilizing

minitablets."

Navamedic ASA will oversee the launch and marketing in Sweden, Norway and

Denmark. Orion Corporation ("Orion") has been granted exclusive rights to

market, distribute, and sell the product across 27 European countries. As the

marketing authorization (MA) holder within their designated territory, Orion

will assume all associated rights and responsibilities.

For further information, please contact:

Kathrine Gamborg Andreassen

CEO,

Navamedic

Mobile: +47 951

78 680

E-mail: kathrine@navamedic.com

About Navamedic ASA

Navamedic ASA is a leading company in the pharmaceutical industry, committed to

delivering innovative healthcare solutions to improve patient outcomes. With a

strong presence in Scandinavia and partnerships across Europe, Navamedic

continues to expand its portfolio and enhance its impact in the healthcare

sector.

About Orion Corporation

Orion is a globally operating Nordic pharmaceutical company - a builder of well

-being for over a hundred years. We develop, manufacture and market human and

veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an

extensive portfolio of proprietary and generic medicines and consumer health

products. The core therapy areas of our pharmaceutical R&D are oncology and

pain. Proprietary products developed by Orion are used to treat cancer,

neurological diseases and respiratory diseases, among others. In 2024 Orion's

net sales amounted to EUR 1,542 million and the company employed about 3,700

professionals worldwide, dedicated to building well-being. Orion's A and B

shares are listed on Nasdaq Helsinki.